France-based specialty diagnostic solutions provider Diaxonhit and XDx in the US, have entered into a memorandum of agreement (MoU) for the exclusive license to market and perform AlloMap Molecular Expression Testing (AlloMap) in Europe.
Developed and marketed by XDx, AlloMap is a diagnostic blood test, which is used by physicians to identify heart transplant recipients who have a low probability of acute cellular rejection.
The CLIA certified blood testing solution has been sold in the US since 2005, which also received clearance from FDA and received CE marking in Europe in 2011.
XDx CEO Peter Maag said that the licensing and distribution agreement will be significantly beneficial for heart transplant recipients across Europe.
The company said that in Europe, the AlloMap test will be carried out centrally by an internationally recognized French laboratory, which will ensure high quality AlloMap testing at the rapid turnaround time.
Based in Brisbane, California, XDx operates as a molecular diagnostics company concentrating on the discovery, development and commercialization of clinically differentiated, high value, non-invasive tests to monitor immune status in transplant recipients.